Novel Cell-based Therapy to Treat Muscle Atrophy Associated with Peripheral Nerve Injury
Abstract
During this performance period, CSInc developed a stable therapeutic formulation which allows for direct and localized injection of human iPSC motoneuron cells, designed to promote motoneuron cell growth and nerve connection, and thus minimize muscle atrophy induced by peripheral nerve injury. This formulation can be readily prepared and injected for studies and treatments. CSInc has continued to work on formulation which can be readily stored in cryogenic conditions (liquid nitrogen) for ease of transport and storage as a viable treatment in hospital settings. In conjunction with our surgical partners at MGH, animal studies were initiated using Lewis rats to monitor and observe the effects of the CSInc therapeutic formulation on sciatic nerve injury (with both repair and no repair) and gastroc muscle atrophy over the course of 28 days. All rats were additionally given daily tacrolimus treatment to inhibit immunorejection of the xenographic motoneuron treatment. Results of the rat studies were quantitatively and qualitatively measured using standard metrics including walking track observations and post-euthanasia gastroc muscle mass comparisons. Rat studies are currently ongoing.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2020
- Accession Number
- AD1117131
Entities
People
- Madeline Vara
- Mitchell Zakin
- Philip Graf
- Piercen Oliver